412 related articles for article (PubMed ID: 32483737)
1. Natural Killer Cell Immunotherapy for Osteosarcoma.
Tullius BP; Setty BA; Lee DA
Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cells for osteosarcoma.
Tarek N; Lee DA
Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
4. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
5. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.
Fernández L; Valentín J; Zalacain M; Leung W; Patiño-García A; Pérez-Martínez A
Cancer Lett; 2015 Nov; 368(1):54-63. PubMed ID: 26276724
[TBL] [Abstract][Full Text] [Related]
6. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.
Kisseberth WC; Lee DA
Front Vet Sci; 2021; 8():672361. PubMed ID: 34164452
[TBL] [Abstract][Full Text] [Related]
7. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
Lin C; Horwitz ME; Rein LAM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
[TBL] [Abstract][Full Text] [Related]
8. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect.
Kiany S; Gordon N
Methods Mol Biol; 2016; 1441():285-95. PubMed ID: 27177675
[TBL] [Abstract][Full Text] [Related]
9. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell-based strategies for immunotherapy of cancer.
Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
[TBL] [Abstract][Full Text] [Related]
11. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL).
Chu Y; Lamb M; Cairo MS; Lee DA
Curr Treat Options Oncol; 2022 Mar; 23(3):381-403. PubMed ID: 35258793
[TBL] [Abstract][Full Text] [Related]
12. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
13. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
[TBL] [Abstract][Full Text] [Related]
14. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target.
Zhu Y; Huang B; Shi J
Oncotarget; 2016 Jul; 7(30):47163-47172. PubMed ID: 27323411
[TBL] [Abstract][Full Text] [Related]
16. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
[TBL] [Abstract][Full Text] [Related]
18. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells and cancer therapy, what we know and where we are going.
Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells in antitumour adoptive cell immunotherapy.
Laskowski TJ; Biederstädt A; Rezvani K
Nat Rev Cancer; 2022 Oct; 22(10):557-575. PubMed ID: 35879429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
